Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer
Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer
复制标题
DOI：
10.1016/j.clinbiochem.2010.04.004
复制
发表时间：
2010-07-01
影响因子：
2.8
通讯作者：
Kalousova, Marta
中科院分区：
文献类型：
--
作者：
Krechler, Tomas;Jachymova, Marie;Kalousova, Marta
目的：晚期糖基化终产物受体（RAGE）参与许多疾病的发病机制，包括糖尿病和癌症。age前体通过乙二醛酶（GLO）解毒。可溶性RAGE是一种通过RAGE介导的病理作用抑制剂。目的是研究胰腺癌（PC）患者的RAGE （AGER）和GLO基因的sRAGE和多态性。设计和方法：研究组包括51例PC患者（34例糖耐量-IGT受损，17例无IGT）， 34例2型糖尿病患者和154例对照组。为了进行遗传分析，患者人数增加到170人。ELISA检测血清sRAGE， PCR-RFLP检测所有多态性（RAGE -429T/C、-374T/A、2184A/G、Gly82Ser和GLO A419C）并测序。结果：与DM患者和对照组相比，PC患者的可溶性RAGE降低(975 +/- 532 vs. 1416 +/- 868 vs. 1723 +/- 643 pg/mL, p
Objectives: The receptor for advanced glycation end-products (RAGE) takes part in the pathogenesis of many diseases, including diabetes mellitus and cancer. AGE-precursors are detoxified by glyoxalase (GLO). sRAGE, soluble RAGE, is an inhibitor of pathological effects mediated via RAGE. The aim was to study sRAGE and polymorphisms of RAGE (AGER) and GLO genes in patients with pancreas cancer (PC).Design and Methods: The studied group consisted of 51 patients with PC (34 with impaired glucose tolerance-IGT, 17 without IGT), 34 type 2 DM and 154 controls. For genetic analysis, the number of patients was increased to 170. Serum sRAGE was measured by ELISA and all polymorphisms (RAGE -429T/C, -374T/A, 2184A/G, Gly82Ser and GLO A419C) were determined by PCR-RFLP and confirmed by sequencing.Results: Soluble RAGE is decreased in patients with PC compared to patients with DM and controls (975 +/- 532 vs. 1416 +/- 868 vs. 1723 +/- 643 pg/mL, p